» Articles » PMID: 9412579

CD23 Deficient Mice Develop Allergic Airway Hyperresponsiveness Following Sensitization with Ovalbumin

Overview
Specialty Critical Care
Date 1997 Dec 31
PMID 9412579
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

The low affinity receptor for IgE (CD23) is reported to regulate immune and inflammatory events and as a result, it may have a role in the development of allergic airway inflammation and hyperresponsiveness (AHR). To test this hypothesis CD23-deficient mice were studied following different modes of allergic sensitization. Mice were actively sensitized either intraperitoneally with ovalbumin (OA)/alum or via the airways (10 days exposure to OA aerosol with no adjuvant). Passive sensitization was performed by intravenous injections of OA-specific IgE. Airway responsiveness, serum IgE and IgG levels were assessed together with airway inflammation. Passive sensitization followed by airway challenges resulted in increased OA-specific lgG and IgE in the serum of wild-type mice only, while both the CD23+/+ and CD23-/- groups developed tracheal smooth muscle hyperresponsiveness to electrical field stimulation, indicating that IgE/CD23-mediated immune functions may not be necessary for the development of allergic changes. Active sensitization of both CD23-/- and CD23+/+ mice resulted in increased serum levels of OA-specific IgE and lgG, airway eosinophilia and significant AHR when compared with nonsensitized mice. The genetic deficiency of CD23-/- mice not only failed to prevent but was associated with a significant increase of these responses. These results indicate that CD23 may not be essential for the development of allergen-induced AHR and further, that its presence may have some inhibitory effects on the allergic response.

Citing Articles

A Comparison of Natural and Therapeutic Anti-IgE Antibodies.

Vogel M, Engeroff P Antibodies (Basel). 2024; 13(3).

PMID: 39051334 PMC: 11270207. DOI: 10.3390/antib13030058.


IgE-neutralizing UB-221 mAb, distinct from omalizumab and ligelizumab, exhibits CD23-mediated IgE downregulation and relieves urticaria symptoms.

Kuo B, Li C, Chen J, Shiung Y, Chu C, Lee C J Clin Invest. 2022; 132(15).

PMID: 35912861 PMC: 9337824. DOI: 10.1172/JCI157765.


The role of CD23 in the regulation of allergic responses.

Engeroff P, Vogel M Allergy. 2020; 76(7):1981-1989.

PMID: 33378583 PMC: 8359454. DOI: 10.1111/all.14724.


Inhibition of CD23-mediated IgE transcytosis suppresses the initiation and development of allergic airway inflammation.

Palaniyandi S, Liu X, Periasamy S, Ma A, Tang J, Jenkins M Mucosal Immunol. 2015; 8(6):1262-74.

PMID: 25783969 PMC: 4575230. DOI: 10.1038/mi.2015.16.


Lymphocyte-based model systems for allergy research: a historic overview.

Neunkirchner A, Schmetterer K, Pickl W Int Arch Allergy Immunol. 2014; 163(4):259-91.

PMID: 24777172 PMC: 7617143. DOI: 10.1159/000360163.